Pathophysiological, methodological, and statistical considerations in CGRP monoclonal antibody therapy: A comment on Imai et al.

Key Points

• To address concerns regarding the interpretation and statistical methodologies used in a recent observational study on CGRP monoclonal antibodies.
• Commentary on the observational study conducted by Imai et al. concerning CGRP monoclonal antibody therapy.
• Analysis of statistical modeling and its implications on the reported data.
• Discussion of pathophysiological and methodological considerations.
• Identified issues in the interpretation of CGRP monoclonal antibody data.
• Highlighted the need for clearer statistical methodologies in reporting.
• Emphasized the importance of accurate representation of real-world data in clinical studies.